menu
    • menu
    [{"orgOrder":0,"company":"Oncocross","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Undisclosed","year":"2022","type":"Not Applicable","leadProduct":"OC514","moa":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Oncocross","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"","sponsorNew":"Oncocross \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Oncocross \/ Not Applicable"},{"orgOrder":0,"company":"Oncocross","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Undisclosed","year":"2023","type":"Not Applicable","leadProduct":"OC514","moa":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Oncocross","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"","sponsorNew":"Oncocross \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Oncocross \/ Not Applicable"},{"orgOrder":0,"company":"Oncocross","sponsor":"JW Pharmaceutical Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2024","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Oncocross","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Oncocross \/ JW Pharmaceutical Corporation","highestDevelopmentStatusID":"4","companyTruncated":"Oncocross \/ JW Pharmaceutical Corporation"}]

    Find Clinical Drug Pipeline Developments & Deals by Oncocross

    Menu

    Oncocross

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Oncocross

                            South Korea arrow
                            CPHI Middle east
                            Not Confirmed

                            Oncocross

                            South Korea arrow
                            CPHI Middle east
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : JW Pharmaceutical Corporation

                            Deal Size : Undisclosed

                            Deal Type : Expanded Collaboration

                            DEALS_DEV arrow-down

                            Oncocross Expands Collaboration with JW Pharmaceutical on AI Drug Development

                            Details : The companies will identify and verify development possibilities for new indications for first-in-class drug pipeline that JW Pharmaceutical is developing in anticancer and regenerative medicine.

                            Brand Name : Undisclosed

                            Molecule Type : Undisclosed

                            Upfront Cash : Undisclosed

                            May 27, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : JW Pharmaceutical Corporation

                            Deal Size : Undisclosed

                            Deal Type : Expanded Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Oncocross

                            South Korea arrow
                            CPHI Middle east
                            Not Confirmed

                            Oncocross

                            South Korea arrow
                            CPHI Middle east
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OC514

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Oncocross Completes Phase I Global Clinical Trial of OC514, Treatment for Sarcopenia

                            Details : Oncocross is developing OC514 as a drug-drug combination product designed to prevent or treat sarcopenia and other rare muscular diseases, using Oncocross’ proprietary AI platform RAPTOR AI™.

                            Brand Name : OC514

                            Molecule Type : Undisclosed

                            Upfront Cash : Not Applicable

                            May 10, 2023

                            Lead Product(s) : OC514

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Oncocross

                            South Korea arrow
                            CPHI Middle east
                            Not Confirmed

                            Oncocross

                            South Korea arrow
                            CPHI Middle east
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OC514

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Oncocross Launches Global Clinical Trials for AI-based Sarcopenia Treatment

                            Details : Oncocross obtained Australia’s TGA approval on phase I IND application for OC514, aims to evaluate the safety, pharmacokinetics, and pharmacodynamics for targeting muscular diseases including sarcopenia.

                            Brand Name : OC514

                            Molecule Type : Undisclosed

                            Upfront Cash : Not Applicable

                            February 25, 2022

                            Lead Product(s) : OC514

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth